Aptorum Group and DiamiR Biosciences Announce Two Abstracts Accepted for Presentation at CTAD 2025 Conference

Wednesday, Nov 19, 2025 8:02 am ET1min read
APM--

DiamiR Biosciences and Aptorum Group announced two poster presentations at the Clinical Trials on Alzheimer's Disease (CTAD) 2025 Conference. The presentations highlight the potential of brain-enriched and inflammation-associated microRNAs as epigenetic biomarkers of neurodegeneration. The studies were funded by the Small Business Innovation Research Grant from the National Institute on Aging. The merger between Aptorum Group and DiamiR Biosciences is expected to close in the first quarter of 2026.

Aptorum Group and DiamiR Biosciences Announce Two Abstracts Accepted for Presentation at CTAD 2025 Conference

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet